Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer.

Journal: Seminars in cancer biology
PMID:

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.

Authors

  • Kate Murray
    Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom.
  • Lucy Oldfield
    Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom.
  • Irena Stefanova
    Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom.
  • Manuel Gentiluomo
    Department of Biology, University of Pisa, Italy.
  • Paolo Aretini
    Fondazione Pisana per la Scienza ONLUS, Italy.
  • Rachel O'Sullivan
    Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom.
  • William Greenhalf
    Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom.
  • Salvatore Paiella
    Pancreatic Surgery Unit, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Italy.
  • Mateus N Aoki
    Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Brazil.
  • Aldo Pastore
    Fondazione Pisana per la Scienza, Scuola Normale Superiore di Pisa, Italy.
  • James Birch-Ford
    Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom.
  • Bhavana Hemantha Rao
    Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Czech Republic.
  • Pinar Uysal-Onganer
    School of Life Sciences, Cancer Mechanisms and Biomarkers Group, The University of Westminster, United Kingdom.
  • Caoimhe M Walsh
    Department of Surgery and Cancer, Imperial College London, United Kingdom.
  • George B Hanna
    Department of Surgery and Cancer, Imperial College London, United Kingdom.
  • Jagriti Narang
    Department of Biotechnology, Jamia Hamdard, New Delhi 110062, India.
  • Pradakshina Sharma
    Department of Biotechnology, Jamia Hamdard, India.
  • Daniele Campa
    Department of Biology, University of Pisa, Via Luca Ghini, 13 - 56126, Pisa, Italy. Electronic address: daniele.campa@unipi.it.
  • Cosmeri Rizzato
    Department of Biology, University of Pisa, Italy.
  • Andrei Turtoi
    Tumor Microenvironment and Resistance to Treatment Lab, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, France.
  • Elif Arik Sever
    Institute of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Turkiye.
  • Alessio Felici
    Department of Biology, University of Pisa, Via Luca Ghini, 13 - 56126, Pisa, Italy. Electronic address: alessio.felici@phd.unipi.it.
  • Ceren Sucularli
    Department of Bioinformatics, Hacettepe University, Turkiye.
  • Giulia Peduzzi
    Department of Biology, University of Pisa, Via Luca Ghini, 13 - 56126, Pisa, Italy. Electronic address: giulia.peduzzi@biologia.unipi.it.
  • Elif Öz
    Department of Biostatistics and Bioinformatics, Acibadem Mehmet Ali Aydinlar University, Turkiye.
  • Osman Ugur Sezerman
    Department of Biostatistics and Medical Informatics, Acıbadem University, Istanbul, Turkey. Electronic address: ugur.sezerman@acibadem.edu.tr.
  • Robert van der Meer
  • Nathan Thompson
    University of Strathclyde, United Kingdom.
  • Eithne Costello
    Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom. Electronic address: ecostell@liverpool.ac.uk.